Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.36 |
| ▸ | RARG | P13631 | 3/20 | 0.31 |
| ▸ | RARB | P10826 | 2/20 | 0.31 |
| ▸ | F2 | P00734 | 2/20 | 0.31 |
| ▸ | F9 | P00740 | 2/20 | 0.31 |
| ▸ | F10 | P00742 | 2/20 | 0.31 |
| ▸ | CFD | P00746 | 2/20 | 0.31 |
| ▸ | PLG | P00747 | 2/20 | 0.31 |
| ▸ | PLAU | P00749 | 2/20 | 0.31 |
| ▸ | PLAT | P00750 | 2/20 | 0.31 |
| ▸ | F11 | P03951 | 2/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.31 |
| ▸ | F7 | P08709 | 2/20 | 0.31 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613895 | 0.89 | CYP26A1 (0.36) | CYP26A1CYP26B1RARGRARBF2 | |
| SCHEMBL13606599 | 0.86 | CYP26A1 (0.35) | CYP26A1CYP26B1RARGRARBRARA | |
| SCHEMBL13613877 | 0.79 | LTB4R (0.39) | CYP26A1CYP26B1 | |
| SCHEMBL13613897 | 0.79 | PTGS2 (0.39) | CYP26A1CYP26B1 | |
| SCHEMBL13606598 | 0.76 | CYP26A1 (0.35) | CYP26A1CYP26B1RARGRARBRARA | |
| SCHEMBL6754602 | 0.73 | CYP26A1 (0.41) | CYP26A1CYP26B1RARGRARBRARA | |
| SCHEMBL4517348 | 0.68 | CYP26A1 (0.35) | CYP26A1CYP26B1 | |
| SCHEMBL4512171 | 0.67 | RARB (0.44) | CYP26A1CYP26B1RARGRARBRARA | |
| SCHEMBL4519574 | 0.65 | CYP26A1 (0.36) | CYP26A1CYP26B1RARGRARBRARA | |
| SCHEMBL4511877 | 0.65 | CYP26A1 (0.36) | CYP26A1CYP26B1RARGRARBRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | CYP26A1 15/4885CYP26B1 10/4885RARG 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.